Monitor for follow-up announcements after the April 16 presentation that may signal new partnerships or financing deals. Absent such news, the current funding risk highlighted in the 20-F remains unresolved.
Price Chart
Executive Summary
Innate Pharma announced it will present at the AACR 2026 Oncology Industry Partnering Event, highlighting its clinical pipeline including IPH4502 and lacutamab. This provides a platform to attract potential partners and investors amid ongoing funding challenges.
Key Facts
- Innate Pharma will present at the AACR 2026 Oncology Industry Partnering Event on April 16, 2026.
- Yannis Morel, COO, will present in Showcase Session 2 focused on oncology pipelines and innovation.
- The company will highlight progress on key assets: IPH4502 (Nectin-4 ADC) and lacutamab (anti-KIR3DL2 antibody).
- The event targets venture capitalists, biotech/pharma leaders, and investors, offering partnership and financing opportunities.
- This announcement follows a recent 20-F filing that raised going-concern doubts due to a funding gap.
Financial Impact
No immediate financial impact disclosed; potential for future non-dilutive financing or partnerships.
Risk Factors
- Continued reliance on non-dilutive financing or partnerships to extend cash runway beyond Q3 2026.
- Failure to secure partnerships could lead to dilutive equity raises or operational constraints.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-024144 |
| Document: a260408_6k-iph.htm | 0001628280-26-024144 |
| Document: 0001628280-26-024144-index-headers.html | 0001628280-26-024144 |
| Document: 0001628280-26-024144-index.html | 0001628280-26-024144 |
| Document: 0001628280-26-024144.txt | 0001628280-26-024144 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 19, 2026 23w ago | 6-K | $2.25 $1.65 | ▼ −26.67% | ▼ −32.96% | $1.51 (−32.93%) |
May 13, 2026 23w ago | 6-K | $1.50 $1.65 | ▼ −10.00% | ▼ −5.56% | $1.51 (−0.60%) |
May 6, 2026 24w ago | 6-K | $1.50 $1.65 | ▲ +10.00% | ▲ +7.94% | $1.51 (+0.60%) |
Apr 23, 2026 26w ago | 6-K | $1.50 $1.65 | ▲ +10.00% | ▲ +4.98% | $1.51 (+0.60%) |
Apr 17, 2026 27w ago | 6-K | $1.50 $1.65 | ▲ +10.00% | ▲ +3.86% | $1.51 (+0.60%) |
Apr 13, 2026 28w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +11.25% | $1.51 (+9.91%) |
Apr 13, 2026 28w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +11.25% | $1.51 (+9.91%) |
Apr 8, 2026 28w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +9.72% | $1.51 (+9.91%) |
Apr 3, 2026 29w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +6.71% | $1.51 (+9.91%) |
Apr 1, 2026 29w ago | 20-F | $1.37 $1.65 | ▼ −20.17% | ▼ −6.80% | $1.51 (−9.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers